FDA Commissioner Hahn To Seek Public Health Leadership Post To Work On COVID-19 Issues Next

Outgoing US FDA chief Stephen Hahn has signaled that he’ll seek a posting in public health, where he can increase equity and help in the fight against COVID-19.

Stephen Hahn of MD Anderson Cancer Center is expected to be nominated for FDA commissioner

Outgoing US Food and Drug Administration commissioner Stephen Hahn has signaled that he wants to focus on public health issues in his next career, and continue to address the types of challenges the agency will face in 2021 in approving the best diagnostics testing for COVID-19 and its variants.

Hahn laid out his accomplishments at the FDA over the past year, and issues the agency is having in fighting the pandemic, in a wide-ranging press briefing with health care...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

Execs On The Move: 5-9 May 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By 

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.

Execs On The Move: 28 April - 2 May 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

More from Medtech Insight

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By 

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.